Platelets for neonatal transfusion - Study 2: A randomised controlled trial to compare two different platelet count thresholds for prophylactic platelet transfusion to preterm neonates

Anna Curley, Vidheya Venkatesh, Simon Stanworth, Paul Clarke, Timothy Watts, Helen New, Karen Willoughby, Rizwan Khan, Priya Muthukumar, Alison Deary

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


Introduction: Neonatal thrombocytopenia is a common and important clinical problem in preterm neonates. A trial assessing clinically relevant outcomes in relation to the different platelet count thresholds used to trigger transfusion has never been undertaken in preterm neonates with severe thrombocytopenia. Objectives: Platelets for Neonatal Transfusion - Study 2 (PlaNeT-2) aims to assess whether a higher prophylactic platelet transfusion threshold is superior to the lower thresholds in current standard practice in reducing the proportion of patients who have a major bleed or die up to study day 28. Methods: PlaNeT-2 is a two-stage, randomised, parallel-group, superiority trial. PlaNet-2 compares clinical outcomes in preterm neonates (<34 weeks' gestation at birth) randomised to receive prophylactic platelet transfusions to maintain platelet counts at or above either 25 × 109/l or 50 × 10 9/l. The primary outcome measure is the proportion of patients who either die or experience a major bleed up to and including study day 28. A total of 660 infants will be randomised. Results and Conclusions: This trial will help define optimal platelet transfusion support for severely thrombocytopenic preterm neonates by evaluating the risks and benefits of two different prophylactic neonatal platelet transfusion thresholds.

Original languageEnglish
Pages (from-to)102-106
Number of pages5
Issue number2
Publication statusPublished - Aug 2014
Externally publishedYes


  • Newborn
  • Platelets
  • Thrombocytopenia
  • Transfusion

Cite this